Abstract

COMPARATIVE EVALUATION OF THE CLINICAL, BIOCHEMICAL AND IMAGING OUTCOMES OF SAROGLITAZAR AND VITAMIN E IN NON-ALCOHOLIC FATTY LIVER DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY

Sreemantula Divya*, Asthapuram Sahaja, Sakkeri Nikitha, Sutharapu Divya, Dr. Moka Praneeth and Dr. Tirunagari Mamatha

.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. The objective of this study to assess the comparative efficacy of Saroglitazar and Vitamin E in improving Non-Alcoholic Fatty Liver Disease patients (NAFLD). The study design is a prospective observational study conducted for a period of 6 months with a sample size of 104 patients. Result was conducted a comparative evaluation of the clinical, biochemical, and imaging outcomes of Saroglitazar and Vitamin E in patients with Non- Alcoholic Fatty Liver Disease (NAFLD). The results demonstrate that Saroglitazar provides superior outcomes in several key areas, including lipid profile management, glycemic control, and reduction in liver fibrosis as compared to Vitamin E. the conclusion of this study is a Saroglitazar outperformed Vitamin E in improving lipid profiles, glycemic control, and liver fibrosis in NAFLD patients, making it the more effective treatment option. Vitamin E showed benefits primarily in reducing liver enzymes but was less impactful overall. Saroglitazar is suggested as the preferred choice, especially for patients with metabolic complications.

Keywords: Non-alcoholic fatty liver disease, Saroglitazar, Vitamin E and diabetes.